Phospho-WWOX (Y33) Antibody

What is Phospho-WWOX (Y33) and why is it important in cellular signaling?

Phospho-WWOX (Y33) refers to the WW domain-containing oxidoreductase protein when specifically phosphorylated at tyrosine 33 within its first WW domain. This phosphorylation is crucial in cellular signaling for several reasons:

• It serves as a regulatory switch that alters WWOX's binding capacity to numerous protein partners

• Y33 phosphorylation is mediated primarily by Src kinase and occurs in response to genotoxic stress

• When phosphorylated at Y33, WWOX gains expanded binding capabilities beyond the canonical PPxY motif recognition

• This phosphorylation regulates interactions with key proteins including p73, p53, and MAPK8, affecting multiple downstream signaling pathways

The importance of this phosphorylation site is evidenced by the fact that mutation of Y33 to arginine (Y33R) abolishes many of WWOX's protein-protein interactions and alters its subcellular localization and function .

What are the main applications of Phospho-WWOX (Y33) antibodies in research?

Phospho-WWOX (Y33) antibodies have several key applications in research:

These antibodies are particularly valuable for studying:

• Cancer progression and tumor suppression mechanisms

• Neurodegeneration pathways involving WWOX

• Apoptotic signaling through WWOX-p73 interactions

• DNA damage response pathways

How does Y33 phosphorylation affect WWOX protein function?

Y33 phosphorylation significantly alters WWOX protein function in several ways:

• Enhanced protein binding: Phosphorylation of Y33 by Src kinase enhances WWOX binding to p73 several-fold compared to non-phosphorylated WWOX

• Altered subcellular localization: pY33-WWOX can sequester nuclear proteins like p73 in the cytoplasm, thereby modulating their transcriptional activity

• Expanded binding repertoire: While non-phosphorylated WWOX primarily binds proteins containing PPxY motifs through its first WW domain, pY33-WWOX gains the ability to interact with proteins lacking this motif

• Proapoptotic activity regulation: Y33 phosphorylation is important for WWOX's proapoptotic function, as mutations at this site (Y33R) significantly reduce WWOX's ability to induce apoptosis

• Transcriptional regulation: By sequestering transcription factors in the cytoplasm, pY33-WWOX can suppress their transcriptional activity, as demonstrated with p73

What are the recommended protocols for detecting Phospho-WWOX (Y33) in Western blot analysis?

For optimal Western blot detection of Phospho-WWOX (Y33):

Sample preparation:

• Use cell lysates from cells under stress conditions (e.g., PMA treatment, genotoxic stress)

• For induced phosphorylation, treat HepG2 cells with PMA (125ng/ml for 30 minutes)

• Include phosphatase inhibitors in lysis buffer to preserve phosphorylation status

Protocol specifics:

• Load 20-50μg protein per lane on 10% SDS-PAGE gel

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% BSA (preferred over milk for phospho-epitopes)

• Incubate with primary antibody at 1:500-1:2000 dilution overnight at 4°C

• Wash 3-5× with TBST

• Incubate with appropriate secondary antibody

• Visualize using chemiluminescence detection

Essential controls:

• Include a phospho-blocking peptide control to confirm specificity

• Use Y33 mutant (Y33R) as a negative control

• Include Src kinase-treated samples as positive controls

Expected results:

• Predicted band size: 47 kDa

• Verify specificity by phosphopeptide competition

How can researchers validate the specificity of Phospho-WWOX (Y33) antibodies?

Validating specificity of Phospho-WWOX (Y33) antibodies requires multiple approaches:

• Phosphopeptide competition assay:

  • Pre-incubate the antibody with synthetic phosphopeptide containing the Y33 site

  • A true phospho-specific antibody will show diminished or absent signal when blocked

• Phosphatase treatment control:

  • Treat one set of samples with lambda phosphatase before immunoblotting

  • Specific phospho-antibodies will show reduced or no signal in treated samples

• Mutagenesis approaches:

  • Compare detection between wild-type WWOX and Y33 mutants (Y33R or Y33F)

  • These mutations abolish phosphorylation at position 33

• Kinase activation/inhibition:

  • Use Src kinase inhibitors to reduce Y33 phosphorylation

  • Alternatively, activate Src to increase phosphorylation and antibody signal

• Knockout/knockdown controls:

  • Use WWOX knockout or knockdown cells/tissues to confirm absence of signal

  • This confirms the antibody is not cross-reacting with other phospho-proteins

As demonstrated in published research, specificity can be confirmed when the antibody detects phosphorylated WWOX in wild-type samples but not in Y33 mutants, and when the signal is competed away by the phosphopeptide .

What are the optimal experimental conditions for studying Phospho-WWOX (Y33) in different cellular contexts?

The optimal conditions vary depending on the cellular context and research question:

Cancer cell lines:

• Baseline Y33 phosphorylation may be detectable in cancer cell lines like HepG2

• Enhanced detection by treating with PMA (125ng/ml for 30 minutes)

• Etoposide treatment can increase endogenous WWOX and p73 levels to study their interaction

Neuronal cells/tissues:

• In neurodegeneration studies, stress stimuli induce Y33 phosphorylation

• Genotoxic stress or TNF treatment may enhance phosphorylation detection

Heterozygous WWOX models:

• Interestingly, heterozygous Wwox mice show dramatically enhanced Y33 phosphorylation in brain cortex (~1-fold increase)

• This provides a valuable model for studying pY33-WWOX function in neurodegeneration

Protein-protein interaction studies:

• Co-expression of WWOX with Src kinase enhances Y33 phosphorylation

• For studying WWOX-p73 interactions, co-transfection of cells with both proteins allows for co-immunoprecipitation studies

Real-time monitoring:

• Förster resonance energy transfer (FRET) microscopy can be used to measure WWOX signaling dynamics

• Time-lapse microscopy with TGF-β1 treatment allows monitoring of WWOX activation and protein binding

How do Src kinase and other factors regulate WWOX Y33 phosphorylation?

Src kinase plays a central role in WWOX Y33 phosphorylation, though multiple regulatory factors are involved:

Src kinase mechanism:

• The first WW domain of WWOX contains a sequence motif recognized by Src-family kinases

• Specifically, a hydrophobic residue (valine) precedes Y33, making it a target for Src phosphorylation

• Direct evidence shows Src can phosphorylate isolated WW1 domain fusions containing Y33 in vitro

Experimental verification of Src-mediated phosphorylation:

• Co-transfection of activated Src with WWOX increases Y33 phosphorylation

• Dominant-negative Src mutants reduce Y33 phosphorylation

• Mutation of Y33 (to F or R) prevents Src-mediated phosphorylation

Other regulatory factors:

• Genotoxic stress induces Y33 phosphorylation

• TNF and TGF-β1 treatments can trigger Y33 phosphorylation

• In heterozygous WWOX models, compensatory mechanisms dramatically increase Y33 phosphorylation, suggesting autoregulatory mechanisms

Phosphorylation specificity:

• Y33 in WW1 is specifically targeted, not Y34 or Y61 in WW2

• When Y33 and Y34 were both mutated to phenylalanine, no phosphorylation was detected, confirming Y33 specificity

The interconnection of these regulatory pathways suggests WWOX phosphorylation serves as an integration point for multiple cellular stress signals.

What is the functional relationship between Phospho-WWOX (Y33) and p73 in apoptotic pathways?

The relationship between Phospho-WWOX (Y33) and p73 in apoptotic pathways is complex and bidirectional:

Binding mechanism:

• Phosphorylated WWOX at Y33 (pY33-WWOX) binds more strongly to p73 than non-phosphorylated WWOX

• This interaction occurs between the first WW domain of WWOX and the PPXY motif in p73

• Mutation of Y33 to arginine (Y33R) abolishes this interaction

Subcellular redistribution:

• Upon binding to pY33-WWOX, p73 is sequestered from the nucleus to the cytoplasm

• This redistribution suppresses p73's transcriptional activity

• Experiments show that co-expression of WWOX with p73 causes dramatic relocalization of p73 from nucleus to cytoplasm

Paradoxical effects on apoptosis:

• While sequestering p73 reduces its transcriptional activity, cytoplasmic p73 contributes to WWOX's proapoptotic function

• Co-transfection of p73β and WWOX markedly increases the number of apoptotic cells compared to either protein alone

• Even transcriptionally inactive ΔNp73 can enhance WWOX-mediated apoptosis when sequestered in the cytoplasm

Experimental evidence:

This complex interplay suggests that WWOX and p73 have both nuclear and cytoplasmic roles in promoting apoptosis, with pY33-WWOX controlling the balance between these mechanisms.

How is the transition from Y33 to S14 phosphorylation in WWOX related to disease progression?

The transition from Y33 to S14 phosphorylation represents a critical regulatory switch in WWOX function with significant implications for disease progression:

Phosphorylation switch mechanism:

• Phosphorylation at Y33 is associated with WWOX's tumor suppressor and apoptotic functions

• A transition to S14 phosphorylation appears to occur during disease progression

• This represents a switch from one set of binding partners to another, altering WWOX signaling outputs

Disease relevance:

• Research indicates that switching from Y33 to S14 phosphorylation enhances disease progression in multiple contexts:

  • Cancer progression

  • Alzheimer's disease development

  • Potentially other neurodegenerative conditions

Partner protein dynamics:

• pY33-WWOX has an expanded set of binding partners not dependent on the PPxY motif

• Many pY33-WWOX-interacting proteins (marked in red in some research papers) participate in neuropathological events in vivo

• For example, pY33-WWOX binds JNK and ERK and blocks hyperphosphorylation of tau by these enzymes

• pY33-WWOX also binds proteins like TPC6A, TPC6A∆, and TIAF1, preventing their aggregation in the brain

Experimental approaches to study this transition:

• Phospho-specific antibodies for both modifications are essential tools

• Time-course experiments following stress induction can reveal the temporal relationship between these phosphorylation events

• Mutation studies (Y33F/R and S14A/D) can help dissect the functional consequences of each modification

This phosphorylation switch mechanism represents a promising area for therapeutic intervention, as maintaining Y33 phosphorylation or preventing S14 phosphorylation might slow disease progression.

What challenges are commonly encountered when using Phospho-WWOX (Y33) antibodies and how can they be overcome?

Researchers face several challenges when working with Phospho-WWOX (Y33) antibodies:

Challenge 1: Low endogenous phosphorylation levels

• Solution: Stimulate cells with PMA (125ng/ml for 30 minutes), etoposide, or other stressors before analysis

• Alternative: Use Src kinase co-expression to enhance Y33 phosphorylation in experimental systems

Challenge 2: Phospho-epitope instability

• Solution: Include phosphatase inhibitors in all buffers during sample preparation

• Alternative: Process samples quickly and maintain cold temperatures throughout

• Tip: For tissue samples, flash-freeze immediately after collection

Challenge 3: Antibody cross-reactivity

• Solution: Always include a phosphopeptide competition control to confirm specificity

• Alternative: Use Y33 mutant (Y33F/R) samples as negative controls

Challenge 4: Variability between antibody sources and lots

• Solution: Validate each new lot with positive and negative controls

• Alternative: Maintain a reference sample set for standardization across experiments

Challenge 5: Distinguishing between phosphorylated isoforms of WWOX

• Solution: Use multiple antibodies targeting different phosphorylation sites (Y33 vs. S14 vs. Y287)

• Alternative: Employ phosphatase treatment followed by rephosphorylation with specific kinases in vitro

Challenge 6: Spatial-temporal dynamics in living cells

• Solution: Consider FRET-based approaches for real-time monitoring of phosphorylation events

• Alternative: Use time-course experiments with fixed cells at different timepoints

How can researchers optimize immunostaining protocols for Phospho-WWOX (Y33) in different sample types?

Optimal immunostaining protocols vary by sample type:

Paraffin-embedded tissue sections:

• Deparaffinize and rehydrate sections using standard protocols

• Perform heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) for 20 minutes

• Cool sections to room temperature (approximately 20 minutes)

• Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

• Block with 5-10% normal serum in PBS for 1 hour at room temperature

• Incubate with Phospho-WWOX (Y33) antibody (1:100-1:300) overnight at 4°C

• Apply secondary antibody and detection system according to standard protocols

• Always include a phosphopeptide blocking control

Cultured cells (immunofluorescence):

• Seed cells on fibronectin-covered cell culture slides

• Fix with 3.7% PBS-buffered formaldehyde for 10 minutes

• Permeabilize with 0.05% Triton X-100 in PBS for 5 minutes

• Block with 10% goat serum in PBS for 1 hour

• Incubate with Phospho-WWOX (Y33) antibody (1:50-1:200) for 1 hour at room temperature

• Apply fluorophore-conjugated secondary antibody and counterstain nuclei

• For co-localization studies with interacting partners (e.g., p73), use differently colored secondary antibodies

Frozen tissue sections:

• Allow sections to equilibrate to room temperature and fix briefly (5 minutes) with cold acetone

• Air dry sections completely

• Rehydrate in PBS for 10 minutes

• Block with 5-10% normal serum with 0.1% Triton X-100

• Incubate with antibody at 1:100-1:300 dilution overnight at 4°C

• Continue with standard detection protocols

How is Phospho-WWOX (Y33) research contributing to our understanding of neurodegenerative diseases?

Phospho-WWOX (Y33) research is providing several important insights into neurodegenerative diseases:

Alzheimer's disease connections:

• pY33-WWOX binds to and prevents aggregation of proteins associated with Alzheimer's disease, including TPC6A, TPC6A∆, and TIAF1

• Switching from Y33 to S14 phosphorylation in WWOX enhances Alzheimer's disease progression

• WWOX gene has been defined as a risk factor for Alzheimer's disease

Tau hyperphosphorylation regulation:

• pY33-WWOX binds JNK and ERK and blocks hyperphosphorylation of tau by these enzymes

• This mechanism may be protective against tau-related pathologies in neurodegenerative diseases

WWOX heterozygosity effects:

Protein aggregation inhibition:

• WWOX interacts with Zfra, which is a potent inhibitor of protein aggregation in Alzheimer's disease progression

• pY33-WWOX appears to prevent protein aggregation in the brain through multiple mechanisms

Future research directions:

• Investigating how modulating the Y33 phosphorylation state might slow neurodegeneration

• Exploring the relationship between WWOX phosphorylation patterns and other neurodegenerative diseases beyond Alzheimer's

• Developing therapeutic approaches targeting the transition from Y33 to S14 phosphorylation

What methodological approaches can be used to study the dynamics of WWOX Y33 phosphorylation in living systems?

Several advanced methodological approaches can be employed to study WWOX Y33 phosphorylation dynamics:

Real-time imaging techniques:

• Förster resonance energy transfer (FRET) microscopy allows real-time monitoring of WWOX phosphorylation and protein interactions in living cells

• Constructs with fluorescent proteins flanking the WWOX protein can detect conformational changes upon phosphorylation

• Time-lapse microscopy with TGF-β1 treatment enables visualization of WWOX activation and protein complex formation

Phosphoproteomics approaches:

• Mass spectrometry-based phosphoproteomics can quantify WWOX phosphorylation at multiple sites simultaneously

• Stable isotope labeling with amino acids in cell culture (SILAC) coupled with phosphopeptide enrichment allows temporal profiling of phosphorylation events

• Targeted multiple reaction monitoring (MRM) can increase sensitivity for detecting specific phosphorylation sites

In vivo models:

• Heterozygous Wwox mice provide a valuable model system, as they show enhanced Y33 phosphorylation in brain cortex

• Phospho-specific antibodies enable immunohistochemical analysis of tissue sections to map phosphorylation patterns

• Tissue-specific conditional knockout models can help assess the importance of WWOX phosphorylation in different contexts

Biosensor development:

• Genetically-encoded biosensors with phospho-binding domains coupled to fluorescent proteins

• Split luciferase complementation assays to detect phosphorylation-dependent protein interactions

• CRISPR-mediated tagging of endogenous WWOX to monitor phosphorylation without overexpression artifacts

Kinase activity manipulation:

• Chemical genetics approaches using analog-sensitive Src kinase mutants

• Optogenetic control of kinase activity to precisely time Y33 phosphorylation

• Small molecule inhibitors or activators of relevant kinases and phosphatases

These methodological approaches, particularly when used in combination, can provide comprehensive insights into the spatial and temporal dynamics of WWOX Y33 phosphorylation in physiological and pathological contexts.

What are the implications of Y33 phosphorylation for WWOX's tumor suppressor function?

The phosphorylation of WWOX at Y33 has multifaceted implications for its tumor suppressor function:

Enhanced pro-apoptotic activity:

• Y33 phosphorylation is critical for WWOX's pro-apoptotic function

• Mutation of Y33 (Y33R) significantly reduces WWOX's ability to induce apoptosis

• Co-expression of wild-type WWOX (which can be phosphorylated at Y33) with p73 markedly increases apoptosis compared to either protein alone

Altered protein-protein interactions:

• Phosphorylation at Y33 enhances WWOX binding to p73, sequestering it in the cytoplasm

• While this reduces p73's transcriptional activity, cytoplasmic p73 contributes to WWOX's pro-apoptotic activity through non-transcriptional mechanisms

• pY33-WWOX has expanded binding capabilities with numerous proteins beyond those containing PPxY motifs

Signaling pathway integration:

• Y33 phosphorylation occurs in response to genotoxic stress and may represent a cellular mechanism to promote apoptosis in damaged cells

• The transition from Y33 to S14 phosphorylation is associated with disease progression, including cancer

• Y33 phosphorylation may function as a signaling node integrating multiple cellular stress signals

Subcellular localization effects:

• Phosphorylation at Y33 influences WWOX's ability to sequester transcription factors in the cytoplasm, preventing their nuclear activity

• This mechanism provides an additional layer of tumor suppression by inhibiting transcriptional programs that might promote survival of damaged cells

Potential therapeutic implications:

• Maintaining Y33 phosphorylation or preventing the switch to S14 phosphorylation might enhance WWOX's tumor suppressor function

• Understanding the kinases and phosphatases that regulate Y33 phosphorylation could identify new therapeutic targets

• The specific binding partners of pY33-WWOX represent potential downstream targets for cancer therapy